Vemurafenib for the treatment of BRAF mutant metastatic melanoma (Q38357122)

2 September 2017

1 reference

title

Vemurafenib for the treatment of BRAF mutant metastatic melanoma (English)

1 reference

2 September 2017

Juan Martin-Liberal

1

1 reference

PubMed ID

25686114

2 September 2017

James Larkin

series ordinal

2

1 reference

PubMed ID

25686114

2 September 2017

language of work or name

English

0 references

publication date

1 February 2015

1 reference

2 September 2017

1 reference

2 September 2017

11

1 reference

2 September 2017

579-589

1 reference

2 September 2017

4

1 reference

2 September 2017

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

Final version of 2009 AJCC melanoma staging and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

Mutation-driven drug development in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

New RAF kinase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

Mammalian MAP kinase signalling cascades

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

B-Raf and the inhibitors: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

Which drug, and when, for patients with BRAF-mutant melanoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

B-Raf mutation: a key player in molecular biology of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

Hepatotoxicity with combination of vemurafenib and ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

Cellular Transforming Genes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

BRAF as therapeutic target in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

Conformation-specific inhibitors of Raf kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

Immune checkpoint blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.252

21 January 2018

Identifiers

DOI

10.2217/FON.14.252

1 reference

2 September 2017

1 reference

PubMed ID

25686114